Nanobiotix (NBTX) Total Non-Current Liabilities (2018 - 2025)

Nanobiotix's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $110.3 million for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 39.1% year-over-year to $110.3 million in Q4 2025; TTM through Dec 2025 was $110.3 million, a 39.1% increase from a year earlier, with the FY2025 full-year figure at $107.0 million, up 35.01% from the prior year.
• Total Non-Current Liabilities advanced to $110.3 million in Q4 2025 per NBTX's latest filing, from $57.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $110.3 million in Q4 2025 and bottomed at $38.7 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $51.7 million (2021), against an average of $58.7 million.
• Across the five-year window, Total Non-Current Liabilities declined 27.73% in 2022 and jumped 60.64% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $43.6 million in 2021, then grew by 14.31% to $49.9 million in 2022, then retreated by 1.04% to $49.3 million in 2023, then soared by 60.64% to $79.3 million in 2024, then jumped by 39.1% to $110.3 million in 2025.
• Per Business Quant, the three latest NBTX Total Non-Current Liabilities figures stand at $110.3 million (Q4 2025), $57.8 million (Q2 2025), and $79.3 million (Q4 2024).